Statin Crestor lowers risk of deep-vein clots without bleeding By Steve Sternberg, USA TODAY 3/29/09
ORLANDO — Researchers have shown for the first time that a potent cholesterol- lowering drug, Crestor, reduces the risk of deep vein thrombosis, or "economy-class syndrome," caused by potentially lethal blood clots that start in the veins and migrate to the lungs, sometimes after long flights. The evidence, out today, is the latest to emerge from the landmark JUPITER trial, which showed that statin treatments can cut in half the risk of heart attacks and strokes even in people with normal cholesterol levels. No other medicine has been shown to safely prevent these blood clots, which occur in at least 350,000 people a year and kill as many as 100,000 of them. The standard remedy once thrombosis has occurred is the drug warfarin, which, unlike statins, can promote bleeding. BETTER LIFE: Get the latest news on heart health Statins are "a remarkably benign therapy," says senior investigator Paul Ridker of Brigham and Women's Hospital in Boston. "The thing that's really exciting is that there is no bleeding risk." FIND MORE STORIES IN: Boston | Prevention | Women | Stanford University | New England Journal of Medicine | University of Wisconsin-Madison | Lipitor | Lancet | Zocor | College of Cardiology | Crestor | Pravachol | C-reactive | Dentistry | University of Rochester School of Medicine | Baystate Medical Center | British-based AstraZeneca PLC | Paul Ridker of Brigham | Robert Glynn JUPITER, released in November, showed that Crestor can prevent heart attacks and strokes in people with normal cholesterol levels — LDL levels of 130 milligrams a deciliter or below — and high levels of C-reactive protein, an ominous sign of artery inflammation. About half of the people who suffer from heart attacks each year have normal cholesterol levels. Other studies have hinted that statins also reduce clot formation, but their power to prevent deep vein thrombosis was unknown. Ridker and his co-workers decided to use JUPITER to test the theory. A total of 17,802 people were randomly assigned to treatment and placebo groups. They were followed for nearly two years, on average.
Deep vein thrombosis occurred in 34 patients taking Crestor and 60 people who were taking placebos, indicating that treatment reduced the risk of clots by 43%. Ridker says
he believes that other statins would also reduce the risk. Lead investigator Robert Glynn, also of Brigham and Women's, calculated that doctors would need to treat 18 people to prevent one event, whether it's a heart attack, stroke or deep vein thrombosis. Mark Hlatky of Stanford University says that life-long statin therapy is the most expensive way to reduce heart risk, especially using potent brand-name versions, which
cost up to $4 a day. The costs decrease to about $1 a day using generics, he says, but they are not as potent as newer drugs. The study was released at a scientific meeting of the American College of Cardiology here and in the New England Journal of Medicine.
Members’ Wel -Being – Stress Management Introduction Stress is the "wear and tear" our bodies experience as we adjust to our continually changing environment. Whether we like it or not, stress is part and parcel of life. It can affect us both physically and emotionally and can create positive or negative feelings. Stress can be good and we call this positive stress. Positive stress
HIV-infected man living in Zimbabwe purchased zidovudinetablets that, upon analysis, were found to contain no zidovudine. In addition, 60% of tested antimalarial preparations beingsold in Cambodia were found to contain either no active in- Scott R. Penzak,1 Edward P. Acosta,2 Michele Turner,2 Jorge A. Tavel,3 gredient or inferior substitutes . To this end, we assessed and Henry Masur4